Senores Pharmaceuticals Limited (BOM:544319)

Market Cap	47.65B +108.6%
Revenue (ttm)	6.33B +58.9%
Net Income	1.16B +98.7%
EPS	26.39 +63.9%
Shares Out	n/a
PE Ratio	40.94
Forward PE	32.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,189
Open	1,044.70
Previous Close	1,048.80
Day's Range	1,036.20 - 1,078.25
52-Week Range	506.00 - 1,193.35
Beta	n/a
Analysts	Strong Buy
Price Target	1,174.25 (+12.59%)
Earnings Date	May 14, 2026

About Senores Pharmaceuticals

Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supp...

• Industry: Pharmaceutical Preparations
• Founded: 2017
• Employees: 194
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544319

Financial Performance

In fiscal year 2026, Senores Pharmaceuticals's revenue was 6.33 billion, an increase of 58.85% compared to the previous year's 3.98 billion. Earnings were 1.16 billion, an increase of 98.74%.

Analyst Summary

According to 4 analysts, the average rating for 544319 stock is "Strong Buy." The 12-month stock price target is ₹1,174, which is an increase of 12.59% from the latest price.

Price Target

₹1,174

(12.59% upside)

Analyst Consensus: Strong Buy